Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Other Operating Expenses: 2023-2025

Historic Other Operating Expenses for Tonix Pharmaceuticals Holding (TNXP) over the last 2 years, with Sep 2025 value amounting to $1.4 million.

  • Tonix Pharmaceuticals Holding's Other Operating Expenses fell 12.09% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 81.66%. This contributed to the annual value of $66.7 million for FY2024, which is 155.65% up from last year.
  • Per Tonix Pharmaceuticals Holding's latest filing, its Other Operating Expenses stood at $1.4 million for Q3 2025, which was down 58.22% from $3.3 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's Other Operating Expenses' 5-year high stood at $62.3 million during Q2 2024, with a 5-year trough of -$28.7 million in Q4 2023.
  • For the 3-year period, Tonix Pharmaceuticals Holding's Other Operating Expenses averaged around $1.8 million, with its median value being $1.4 million (2025).
  • As far as peak fluctuations go, Tonix Pharmaceuticals Holding's Other Operating Expenses spiked by 105.74% in 2024, and later tumbled by 94.75% in 2025.
  • Quarterly analysis of 3 years shows Tonix Pharmaceuticals Holding's Other Operating Expenses stood at -$28.7 million in 2023, then spiked by 104.13% to $1.2 million in 2024, then decreased by 12.09% to $1.4 million in 2025.
  • Its Other Operating Expenses was $1.4 million in Q3 2025, compared to $3.3 million in Q2 2025 and $943,000 in Q1 2025.